Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
March 08 2023 - 8:00AM
Business Wire
- Webinar to be hosted on Tuesday, March 21, 2023 at 12:00 p.m.
ET, register here, or at the link below.
- Dr. Zoltan Szallasi will provide a high-level overview of
synthetic lethality, why synthetic lethality has become a desired
trait for drugs in oncology, and an in-depth look at how Lantern is
leveraging the synthetic lethality of its drug candidate LP-184 for
several solid tumor types.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence (AI) and machine learning (ML) platform to transform
the cost, pace, and timeline of oncology drug discovery and
development, today announced that it will host a virtual key
opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m. ET
focusing on synthetic lethality, the unique and powerful mechanism
of action behind Lantern’s drug candidates LP-184, LP-284, and
LP-100.
The webinar will feature a leading expert on synthetic lethality
in DNA damage repair (DDR) deficient tumors, Zoltan Szallasi, M.D.,
who serves joint appointments as group leader of the Translational
Cancer Genomics Department at the Danish Cancer Society Research
Center and as faculty of the Computational Health Informatics
Program (CHIP) and Assistant Professor of Pediatrics at Boston
Children's Hospital, which are affiliated with Harvard Medical
School.
During the webinar, Dr. Szallasi will discuss a broad range of
topics surrounding synthetic lethality, including: a brief history
of synthetic lethality in oncology, how synthetic lethality is
being leveraged to successfully treat cancers with DDR
deficiencies, the promising potential of LP-184’s synthetic
lethality for DDR deficient tumors, and the potential to combine
LP-184 with FDA approved agents to enhance LP-184’s anti-tumor
potency. Details on the webinar and how to register can be found
below:
Virtual KOL Webinar Details:
- When: Tuesday, March 21, 2023 at 12:00 p.m. ET
- Webinar Length: 35 minutes
- Registration Link:
https://us06web.zoom.us/webinar/register/WN_SRl6B_BrRi6SUX8XzJnTrQ
- A replay of the webinar will be available on Lantern’s website
beginning on March 21, 2023.
About the Synthetic Lethality Mechanism of Action and
LP-184:
In oncology drug development, synthetic lethality has become a
highly desired capability for small molecules as it promotes the
selective anti-tumor toxicity of cancer cells, while reducing
potential side effects to normal cells. This mechanism of action
can exploit vulnerabilities in cancer cells, known as DNA damage
repair deficiencies, which are common in 25-30% of solid tumors.
Using synthetic lethality, Lantern’s drug candidate LP-184 has
demonstrated nanomolar potency across a comprehensive number of in
vitro and in vivo preclinical models in solid tumors as well as
adult and pediatric central nervous system cancers. Based on its
synthetic lethality mechanism of action and strong preclinical
results, Lantern is targeting advancing LP-184 to a first-in-human
Phase 1 clinical trial in mid-2023.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® AI and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. By targeting
drugs to patients whose genomic profile identifies them as having
the highest probability of benefiting from the drug, Lantern's
approach represents the potential to deliver best-in-class
outcomes.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® AI platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230308005141/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Lantern’s Monthly Newsletter – SPARK: Sign-up
here
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024